Skip to main content
SpringerLink
Log in

No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia

精神分裂症患者颞上回的大麻素受体密度没有显著性变化

  • Article
  • Published:
Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

Objective

In recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, we investigated the binding density of cannabinoid CB1 receptors in the STG of schizophrenia patients compared to control subjects.

Methods

Quantitative autoradiography was used to investigate the binding densities of [3H]SR141716A (a selective antagonist) and [3H]CP-55940 (an agonist) to the CB1 receptors in the STG. Post-mortem brain tissue was obtained from the NSW Tissue Resource Centre (Australia).

Results

Contrasting to previous findings in the alterations of CB1 receptor densities in the prefrontal, anterior and posterior cingulate cortex of schizophrenia, which were suggested to be associated to impairment of cognition function, no significant difference was found between the schizophrenia and control cases in both [3H]SR141716A and [3H]CP-55940 binding.

Conclusion

We suggest that CB1 receptors in the STG are not involved in the pathology of schizophrenia and the auditory hallucination symptom of this disease.

摘要

目的

近年来研究发现, 在精神分裂症患者的内源性大麻素递质系统会出现异常变化, 而颞上回在精神分裂症的病理生理机制中和幻听症状密切相关。 因此, 对照正常人群, 我们研究了精神分裂症患者颞上回大麻素CB-1受体的密度变化。

方法

采用定量放射自显影技术, 通过[3H]SR141716A(CB-1受体选择性拮抗剂)和 [3H]CP-55940(CB-1受体激动剂)检测颞上回CB-1受体密度水平。 死后脑组织由澳大利亚新南威尔士州组织资源中心提供。

结果

先前研究发现, 精神分裂症患者与认知功能失常相关的额前叶, 前、 后扣带回皮质的CB-1 受体密度水平有异常改变. 与此相反, 本研究发现在精神分裂症患者的由[3H]SR141716A和[3H]CP-55940检测的颞上回大麻素受体密度水平和对照组比较没有显著变化。

结论

我们认为颞上回大麻素CB-1受体和精神分裂症患者的发病及幻听症状无关。

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Degenhardt L, Hall W. Cannabis and psychosis. Curr Psychiat Rep 2002, 4: 191–196.

    Article  Google Scholar 

  2. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 2001, 48: 83–92.

    Article  PubMed  CAS  Google Scholar 

  3. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiat 2001, 58: 322–328.

    Article  PubMed  CAS  Google Scholar 

  4. Johns A: Psychiatric effects of cannabis. Brit J Psychiat 2001, 178: 116–122.

    Article  PubMed  CAS  Google Scholar 

  5. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946–1949.

    Article  PubMed  CAS  Google Scholar 

  6. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686–691.

    Article  PubMed  Google Scholar 

  7. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997, 56: 803–807.

    Article  PubMed  CAS  Google Scholar 

  8. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004, 96: 376–381.

    Article  PubMed  CAS  Google Scholar 

  9. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10: 1665–1669.

    Article  PubMed  CAS  Google Scholar 

  10. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29: 2108–2114.

    Article  PubMed  CAS  Google Scholar 

  11. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103: 9–15.

    Article  PubMed  CAS  Google Scholar 

  12. Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H] SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiat 2004, 28: 355–360.

    Article  CAS  Google Scholar 

  13. Newell KA, Deng C, Huang XF. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 2006, 172: 556–560.

    Article  PubMed  CAS  Google Scholar 

  14. Kim JJ, Crespo-Facorro B, Andreasen NC, O’Leary DS, Magnotta V, Nopoulos P. Morphology of the lateral superior temporal gyrus in neuroleptic naive patients with schizophrenia: relationship to symptoms. Schizophr Res 2003, 60: 173–181.

    PubMed  Google Scholar 

  15. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77: 299–318.

    Article  PubMed  CAS  Google Scholar 

  16. Jablensky A, Hugler H, Von Cranach M, Kalinov K. Kraepelin revisited: a reassessment and statistical analysis of dementia praecox and manic-depressive insanity in 1908. Psychol Med 1993, 23: 843–858.

    Article  PubMed  CAS  Google Scholar 

  17. Keks N, Hill C, Opeskin K, Copolov D, Dean B. Psychiatric diagnosis after death: the problems of accurate diagnosis. In: Dean B, Hyde TM, Kleinman J Ed. The Use of CNS Autopsy Tissue in Psychiatric Research: A Practical Guide. Sydney: Gordon & Breach Science Publishers, 1988, 19–37.

    Google Scholar 

  18. Newell KA, Zavitsanou K, Jew SK, Huang XF. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuro psychopharmacol Biol Psychiatry 2007, 31: 225–233.

    Article  CAS  Google Scholar 

  19. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993, 616: 293–302.

    Article  PubMed  CAS  Google Scholar 

  20. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 1994, 47: 33–40.

    Article  PubMed  CAS  Google Scholar 

  21. Sundram S, Copolov D, Dean B. Clozapine decreases [3H] CP55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn-Schmiedebergs Arch Pharmacol 2005, 371: 428–433.

    Article  PubMed  CAS  Google Scholar 

  22. Gaser C, Nenadic I, Volz HP, Buchel C, Sauer H. Neuroanatomy of “hearing voices”: a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. Cereb Cortex 2004, 14: 91–96.

    Article  PubMed  Google Scholar 

  23. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, Johnes T, Frackowiak RSJ. A functional neuroanatomy of hallucination in schizophrenia. Nature 1995. 378: 176–179.

    Article  PubMed  CAS  Google Scholar 

  24. Lennox BR, Park SB, Medley I, Morris PG, Jones PB. The functional anatomy of auditory hallucinations in schizophrenia. Psychiat Res 2000, 100: 13–20.

    Article  CAS  Google Scholar 

  25. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiat Res 2001, 107: 173–177.

    Article  CAS  Google Scholar 

  26. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58: 315–348.

    Article  PubMed  CAS  Google Scholar 

  27. Vinod KY, Hungund BL. Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert Opin Ther Targets 2006,10: 203–210.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Health Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia

    Chao Deng  (邓超), Mei Han  (韩玫) & Xu-Feng Huang  (黄旭枫)

  2. Schizophrenia Research Institute, Sydney, NSW, 2010, Australia

    Chao Deng  (邓超), Mei Han  (韩玫) & Xu-Feng Huang  (黄旭枫)

Authors
  1. Chao Deng  (邓超)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei Han  (韩玫)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xu-Feng Huang  (黄旭枫)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chao Deng  (邓超).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deng, C., Han, M. & Huang, XF. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neurosci. Bull. 23, 341–347 (2007). https://doi.org/10.1007/s12264-007-0051-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-007-0051-9

Keywords

关键词

CLC number

Search

Navigation